Non-Alcoholic Fatty Liver Disease Responce to Orlistat Therapy in Iraqi Type 2 Diabetic Obese Patients

Abdul Kareem Khazal, Faris

	Non-Alcoholic Fatty Liver Disease Responce to Orlistat Therapy in Iraqi Type 2 Diabetic Obese Patients
Iraqi Postgraduate Medical Journal
Article 1, Volume 6, Issue 4, 2007, Pages 267-271 PDF (0 K)
Author
Faris Abdul Kareem Khazal
Abstract
ABSTRACT: BACKGROUND: Non alcoholic fatty liver disease is now recognised as the most common liver disease. insulin ressistance, Increase serum free fatty acids and oxidants incorporate in the pathogenesis leading to a syndrome extended from Simple mild steatosis to steatohepatitis to cirrhosis. OBJECTIVE: The aim to evaluate the effect of orlistat on features of fatty liver disaese in addition to glucose and lipid profile. METHODS: This is A prospective study of 60 type2 diabetic obese patients had evidence of non alcoholic fatty liver disease on ultrasound examination followed for 4 months with orlistat therapy, and asses BMI, waist circumfrence, glucose control, liver function, lipid profile and ultrasound features before and after 4 months. RESULTS: Orlistat therapy decrease BMI, liver size, echogenisity by U/S, and triglyceride level significantly and increase HDL also significantly,but also decrease FPG, 2hPG, HbA1c, serum cholesterol,ALT and waist circumference with insignificant statistical value, while had no effect on prothrombin time and total serum protein. CONCLUSION: Orlistat therapy is beneficial adjuvant therapy in obese type 2 diabetics , it reduce BMI, and U/S manifestations of NAFLD, it also correct dyslipidemia and possibly had positive effect on glucose control and liver enzymes.
Keywords
Non alcoholic fatly liver disease; Orlistat; Iraqi; diabetics

Statistics Article View: 296 PDF Download: 122